While the investigators emphasize that PLIN4 variants were identified in a selected clinical subpopulation and require replication across larger, multi-ancestry cohorts, the identification of a peripheral fat-storage defect opens immediate avenues for drug discovery.

“Discovering genes that underlie this disease isn’t going to fix the disease,” Robison concluded. “But what it can do is teach us what’s causing the disease in lots of people, and we can use that information to design new treatments.”

The research team plans to analyze primary adipocyte tissue from anorexia patients carrying PLIN4 mutations to observe lipid droplet morphology and metabolic signaling directly, working toward therapies that can target peripheral lipid regulation alongside psychological rehabilitation.